Elliott Management Raises Bid For Riverbed Technology To $21 A Share

Activist hedge fund Elliott Management Corp. has sweetened its offer for Riverbed Technology Inc. (RVBD) to $21.00 a share in cash. Shares are currently up over 4 percent.

In January, Elliott Management had offered to buy Riverbed Technology for $19.00 per share, or a total of about $3.08 billion. Elliott Management owns about 10.5 percent stake in Riverbed Technology and is one of its largest shareholder.

Elliott has made it clear that it will not increase its offer any further in the absence of private diligence.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT